Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reviva Pharmaceuticals Hldg Inc (NQ: RVPH )

1.175 +0.035 (+3.07%)
Streaming Delayed Price Updated: 3:11 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 375,803
Open 1.170
Bid (Size) 1.180 (3)
Ask (Size) 1.190 (11)
Prev. Close 1.140
Today's Range 1.110 - 1.240
52wk Range 0.6000 - 5.670
Shares Outstanding 22,650,266
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-77.87%
-77.87%
1 Month
+3.07%
+3.07%
3 Month
+18.27%
+18.27%
6 Month
-14.86%
-14.86%
1 Year
-71.31%
-71.31%

More News

Read More
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
Via InvestorPlace
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
From The Rosen Law Firm, P.A.
Via Business Wire
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
Via InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
From Virtual Investor Conferences
Via GlobeNewswire
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.